SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is actively trending due to significant community discussion surrounding a recent high-profile speech by Donald Trump, with reactions split between praise for his rhetoric and strong criticism for alleged lies and divisive commentary. This speech, which also reignited conversations around tariffs and past controversies, is sparking polarized debate among retail investors regarding the stock's future trajectory.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle (CRCL) is highly active following a significant Q4 earnings beat driven by accelerating USDC adoption, igniting calls for a short squeeze amidst its high short interest; however, community discussion also highlights ongoing concerns about its valuation, interest rate sensitivity, and the stalled CLARITY Act regarding stablecoin regulation.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is a top trend as the market eagerly anticipates its upcoming earnings, with community discussion intensely focused on whether the results will propel the broader AI sector and major indices or lead to a "sell the news" reaction, amplified by recent headlines about US-China chip export restrictions.

Oddity Tech Ltd. engages in the online retail sale of cosmetics and beauty products. Its products include lipsticks, makeup brushes, mascara, eyelash curlers, and makeup brush cleansers. The company was founded by Oran Holtzman and Shiran Holtzman-Erel on March 23, 2013 and is headquartered in Tel Aviv, Israel.

ODDITY Tech Ltd. - Ordinary Shares - Class A

ODDITY Tech is trending as investors grapple with a surprising revenue decline forecast for the upcoming quarter, which overshadows otherwise strong past results and triggers community debate on the company's immediate challenges versus its solid balance sheet and ongoing share repurchase program.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Mannkind is trending following strong Q4 Tyvaso DPI sales that showed accelerating growth and increased market penetration, with the community eagerly anticipating its upcoming full-year earnings report and potential catalysts like pediatric Afrezza approval. Investors are discussing whether these positive revenue trends and future pipeline developments will overcome historical concerns regarding Afrezza's performance and alleged stock manipulation to drive sustained share price growth.

Hut 8 Corp. operates as a Bitcoin miner that focuses on mining. It provides digital asset mining, hosting, and managed infrastructure operation services. The company was founded on January 27, 2023 and is headquartered in Miami, FL.

Hut 8 Corp

Hut 8 Corp is trending due to its successful pivot into AI data center infrastructure, highlighted by a substantial $7 billion, 15-year deal for its River Bend project with a major hyperscaler. The community largely applauds this strategic shift, noting HUT's strong performance and resilience compared to other crypto-exposed companies amidst market fluctuations.

Workday, Inc. engages in the provision of development of enterprise cloud applications for finance and human resources. It delivers financial management, human capital management and analytics applications designed for companies, educational institutions, and government agencies. The company was founded by David A. Duffield and Aneel Bhusri in 2005 and is headquartered in Pleasanton, CA.

Workday Inc - Ordinary Shares - Class A

Workday Inc

Workday is experiencing a significant sell-off, driven by weaker-than-expected fiscal year 2027 subscription revenue guidance and broader market fears of AI disruption impacting the enterprise software sector. Despite beating recent earnings, community discussion highlights contrasting views on whether the downturn is an overreaction, particularly as major AI companies like OpenAI and Anthropic reportedly utilize Workday's own software.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is trending after its recent financial earnings report showed robust revenue growth from new restaurant openings and spurred analyst price target hikes, despite moderated same-store sales. Community sentiment is sharply divided, with bulls touting its growth story and expansion potential, while bears actively debate its high valuation multiples and tight operating margins compared to industry peers.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending following the unveiling of its new "Sales Assist" agent, expanding its voice AI into retail and telecom, which has ignited intense community discussion ahead of its upcoming earnings report. Investors are keenly anticipating signs of profitability and strong revenue growth, with many eyeing a potential short squeeze given the significant short interest.

Lowe's Companies, Inc. engages in the retail sale of home improvement products. The firm offers products for maintenance, repair, remodeling, home decorating, and property maintenance. It also provides home improvement products in the following categories: appliances, seasonal & outdoor living, lumber, lawn & garden, kitchens & bath, hardware, building materials, millwork, paint, rough plumbing, tools, electrical, flooring, and décor. The company was founded in 1946 and is headquartered in Mooresville, NC.

Lowe`s Cos., Inc.

Lowe's Companies, Inc.

Lowe's is a hot topic after reporting better-than-expected Q4 earnings, though its full-year 2026 guidance for comparable sales and EPS fell short of analyst expectations, fueling discussion around a persistent soft housing market. The community is actively weighing this mixed outlook against recent corporate job cuts and the performance of its peers in the challenging home improvement sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ardelyx (NASDAQ:ARDX) Shares Gap Up Following Insider Buying Activity

Ardelyx (NASDAQ:ARDX) Shares Gap Up Following Insider Buying Activity...

<ul class="summary-bullets"><li>Director David Mott bought 333,333 shares at a weighted average price of $5.84, lifting his stake to more than 3.3 million shares.</li><li>The insider buy followed a mixed Q4 earnings report in which revenue rose to $125.2 million, beating expectations, while earnings remained flat.</li><li>Ibsrela drove the revenue beat, offsetting softer Xphozah sales, and the company guided for Ibsrela revenue of $410 million to $430 million in 2026.</li></ul>Ardelyx shares jumped more than 5% overnight after a board director made a sizable open-market purchase, adding fuel to growing investor confidence in Ibsrela, the company’s flagship constipation drug.<a href="https://stocktwits.com/symbol/ARDX">ARDX stock</a> rose 0.4% on Monday after tumbling 15% on Friday, when the company reported no earnings for the fourth quarter (Q4).<h2 class="st-heading-2">Ardelyx Director Buys 333K Shares In Open Market</h2>According to a new regulatory filing, David Mott, a director at Ardelyx, purchased 333,333 shares of the company’s stock on Friday at a weighted average price of $5.84 per share.The filing shows the purchase was made in multiple open-market transactions, with prices ranging from $5.67 to $6.00. Following the buy, Mott holds over 3.3 million Ardelyx shares.&nbsp;<h2 class="st-heading-2">Ibsrela Drives Q4 Revenue Beat</h2>The insider buy followed Ardelyx’s Q4 earnings report, where revenue rose to $125.2 million, up from $116.1 million a year earlier. The result topped Wall Street expectations of about $119.4 million.The company said the increase was driven largely by higher adoption of Ibsrela, which is approved for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. Growth in Ibsrela helped offset softer sales from Xphozah, Ardelyx’s drug for lowering phosphate levels in patients with chronic kidney disease on dialysis.Earnings per share came in at $0.0, compared with $0.02 in the year-ago quarter and slightly below expectations of $0.01.<h2 class="st-heading-2">Strong 2026 Outlook Anchored By Ibsrela</h2>Alongside the results, Ardelyx expects Ibsrela revenue of $410 million to $430 million in 2026, representing growth of at least 50% from 2025 levels. The company cited improvements in prescribing across target healthcare providers, higher patient engagement, and stronger prescription pull-through. For Xphozah, the company forecast 2026 revenue of $110 million to $120 million, up from $103.6 million in 2025.Ardelyx also said it is running additional programs to evaluate Ibsrela in chronic idiopathic constipation and continues to advance its experimental asset RDX10531 across multiple potential indications.<h2 class="st-heading-2">Analysts Reaffirm Bullish Views</h2>On Monday, Wedbush maintained its $19 price target on Ardelyx shares, implying a 230% upside from current levels. Meanwhile, H.C. Wainwright raised its target by 80% to $18 from $10 on Friday, while reiterating a ‘Buy’ rating.H.C. Wainwright said it was encouraged by Ardelyx securing a new U.S. patent extending to November 2042, covering oral formulations of Tenapor, including Ibsrela and Xphozah. Ardelyx has since confirmed that both drugs are now listed in the FDA’s Orange Book, marking a step that strengthens intellectual property protection.CEO Mike Raab previously said the listing was “an important step in extending protections for our portfolio of first-in-class medicines.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for ARDX was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/rdx_ss_png_9ca239304b.webp" alt="rdx ss.png" width="968" height="140"><figcaption>ARDX sentiment and message volume as of February 24 | Source: Stocktwits</figcaption></figure>One user said, “Maybe retailers will realize now’s the time to buy. Nice buy by mott ”<stembedurl>https://stocktwits.com/mktfixer/message/645684167</stembedurl>Another user said, “Always nice seeing Mr.Mott’s investing in the company. Clearly, he’s in it to win it. He knows what he owns and how the current strategy will be a success. So swell! “<stembedurl>https://stocktwits.com/imlivinit/message/645684336</stembedurl>ARDX stock has declined 1.4% year to date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Ardelyx logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ARDX Stock Jumps Over 5% Overnight As Director Loads Up In Vote Of Confidence For Flagship Constipation Drug

On Monday, Wedbush maintained its $19 price target on Ardelyx shares, implying a 230% upside from current levels.

Equity

Ardelyx (NASDAQ:ARDX) Insider James Parker Brady Sells 2,543 Shares

Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) insider James Parker Brady sold 2,543 shares of the stock in a transaction dated Friday, February 20th. The shares were sold at an average price of...

Ardelyx (NASDAQ:ARDX) Insider John Bishop Sells 3,179 Shares

Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) insider John Bishop sold 3,179 shares of the business's stock in a transaction on Friday, February 20th. The shares were sold at an average price of...

Ardelyx (NASDAQ:ARDX) Insider Joseph James Reilly Sells 4,991 Shares

Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) insider Joseph James Reilly sold 4,991 shares of the company's stock in a transaction on Friday, February 20th. The stock was sold at an average price of...

Ardelyx (NASDAQ:ARDX) Insider Sells $56,130.75 in Stock

Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) insider Mike Kelliher sold 9,595 shares of the business's stock in a transaction that occurred on Friday, February 20th. The shares were sold at an...

Insider Selling: Ardelyx (NASDAQ:ARDX) Insider Sells $47,829.60 in Stock

Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) insider Laura Williams sold 8,176 shares of Ardelyx stock in a transaction on Friday, February 20th. The shares were sold at an average price of $5.85...

Ardelyx (NASDAQ:ARDX) Insider Sells 10,439 Shares

Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) insider Eric Duane Foster sold 10,439 shares of the firm's stock in a transaction on Friday, February 20th. The stock was sold at an average price of...

Insider Selling: Ardelyx (NASDAQ:ARDX) CEO Sells 45,982 Shares of Stock

Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) CEO Michael Raab sold 45,982 shares of the company's stock in a transaction on Friday, February 20th. The shares were sold at an average price of $5.85...

Ardelyx (NASDAQ:ARDX) Director Purchases $1,946,664.72 in Stock

Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) Director David Mott purchased 333,333 shares of the business's stock in a transaction dated Friday, February 20th. The shares were purchased at an...

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

Ahead of earnings, sentiment is split between blowout AI growth and concerns around macro pressure, positioning, and post-ER volatility. How do you see it playing out?

Current Price	$6.56
Prev Close	$5.75
Open	$6.21
Dividend Yield	0.00%
50-Day Moving Average	$6.74
Beta	1.04
Avg. Volume	6.64M
PE Ratio	-22.32

52-Week High	$8.40
52-Week Low	$3.21
Market Capitalization	$1.41B
EPS (Annual)	-$0.2556
Price to Book	8.42
Revenue Per Employee	$832,965.23

ARDX
Ardelyx Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ARDX News

ARDXArdelyx Inc